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Abstract
Preclinical and clinical studies have shown that the application of CD105
+ mesenchymal stem cells (MSCs) is feasible and
may lead to recovery after stroke. In addition, circulating microparticles are reportedly functional in various disease
conditions. We tested the levels of circulating CD105
+ microparticles in patients with acute ischemic stroke. The expression
of CD105 (a surface marker of MSCs) and CXCR4 (a CXC chemokine receptor for MSC homing) on circulating microparticles
was evaluated by flow cytometry of samples from 111 patients and 50 healthy subjects. The percentage of apoptotic CD105
microparticles was determined based on annexin V (AV) expression. The relationship between serum levels of CD105
+/AV
2
microparticles, stromal cells derived factor-1a (SDF-1a), and the extensiveness of cerebral infarcts was also evaluated.
CD105
+/AV
2 microparticles were higher in stroke patients than control subjects. Correlation analysis showed that the levels
of CD105
+/AV
2 microparticles increased as the baseline stroke severity increased. Multivariate testing showed that the
initial severity of stroke was independently associated with circulating CD105
+/AV
2 microparticles (OR, 1.103 for 1 point
increase in the NIHSS score on admission; 95% CI, 1.032–1.178) after adjusting for other variables. The levels of CD105
+/
CXCR4
+/AV
2 microparticles were also increased in patients with severe disability (r=0.192, p=0.046 for NIHSS score on
admission), but were decreased with time after stroke onset (r=20.204, p=0.036). Risk factor profiles were not associated
with the levels of circulating microparticles or SDF-1a. In conclusion, our data showed that stroke triggers the mobilization
of MSC-derived microparticles, especially in patients with extensive ischemic stroke.
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Introduction
Adult stem cells circulate between organs for repair and
maintenance of tissues [1,2]. Circulating progenitor/stem cells
have been reported in patients with ischemic stroke [3–8] and
myocardial infarction [9–11]. Human acute stroke is followed by
large and bursting mobilization of peripheral blood immature
hematopoietic CD34
+ cells, colony-forming cells and long-term
culture initiating cells [6], and the extent of such mobilization is
directly related to neurological and functional recoveries [7,8].
Additionally, it has been reported that there is a correlation
between stroke severity and the number of circulating cells
expressing early stem cell markers [3].
Mesenchymal stem cells (MSCs) may also circulate in patients
with acute ischemic stroke. The circulating MSCs population was
reportedly higher in patients with various disease conditions [12–
14]. Furthermore, the neurorestorative capacity of MSCs, such as
angiogenesis, axonal regeneration, and trophic factor expression,
was increased in MSCs from stroke rats when compared with
normal rats [15]. Preclinical studies showed that increasing
circulating CD105
+ (endoglin, a surface marker of MSCs) MSCs
by exogenous administration was effective in recovery after stroke.
Moreover, intravenous application of CD105
+ MSCs induced
neurogenesis and angiogenesis in animal models of stroke [1,16].
We also recently reported that transplantation of autologous
MSCs was feasible and may be effective in stroke patients with
severe neurologic deficits [17,18]. However, although circulating
MSCs have been reported to be dramatically upregulated by
hypoxia in rats [19], few studies have been conducted to
investigate circulating MSCs in stroke patients.
It was previously believed that microparticles were artifacts
formed by apoptotic cell death. However, this view changed when
the release of these small vesicles was recognized to result from
specific process [20,21]. Microparticles may be a window for
target cells/organs. For example, acute myelogenous leukemia
patients contain elevated blood and bone marrow plasma levels of
CXCR4
+ microparticles. Additionally, a relationship between
CXCR4 expression on parent cells and CXCR4
+ microparticles
was observed [22]. Circulating microparticles are also known to be
functional in various diseases [21–24]. However, circulating
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+ or CXCR4
+ (a CXC chemokine receptor for MSC
homing) microparticles have not been investigated in vivo in
patients with cerebrovascular disease.
In this study, we tested the hypothesis that circulating CD105
+
and CXCR4
+ microparticles are upregulated in acute stroke
patients. The percentage of apoptotic microparticles was also
assessed because it has been reported that apoptotic circulating
progenitor/stem (annexin V
+/CD34
+) cells are increased after
acute myocardial infarcts [25], and apoptotic microparticles may
reflect target cell dysfunction (e.g. annexin V
+ endothelial
microparticles in stroke patients with endothelial dysfunction)
[26]. In the present study, the relationship between serum levels of
CD105
+/annexin V (AV)
2 microparticles, stromal cells derived
factor-1a (SDF-1a, CXCL 12, a chemoattractant of MSCs), and
the extensiveness of cerebral infarcts was evaluated.
Methods
Study Population
Subjects were recruited from the patient population of a
university hospital. We enrolled 111 patients (46 women, mean
age 66.0611.3 years) afflicted with ischemic cerebrovascular
events who were admitted within 24 hours of the onset of the first
symptom. A group of 50 healthy subjects served as a control.
Stroke risk factors and National Institute of Health Stroke Scale
(NIHSS) score were evaluated and peripheral blood samples were
collected from all participants at the time of admission (mean 6
SD, 3.2162.28 days after stroke onset). All human samples were
used in accordance with procedures approved by the Institutional
Review Boards in Samsung Medical Center.
All the patients with ischemic cerebrovascular events underwent
electrocardiography, echocardiography and brain MRI (3.0-tesla,
Achieva, Philips Medical Systems), including diffusion-weighted
imaging (DWI) and MR angiography of the cervical and
intracranial vessels. MRI volume measurements were conducted
by one of the authors who was blinded to the clinical information
using a computer-assisted volumetric analysis program (Medical
Image Processing, Analysis and Visualization, version 2.1, CIT,
NIH). Each patient gave written, informed consent for his or her
involvement and the Institutional Review Boards in Samsung
Medical Center approved the study.
Flow Cytometry
The expression of CD105, CXCR4 and AV on circulating
microparticles was evaluated by flow cytometry. To preclude the
possibility that CD105
+ microparticles are of cerebral endothelial
cell-origin [27,28], we tested the correlation between CD105
+
microparticles and endothelial microparticles (CD 31
+/CD42b
2).
Double labeling with anti-CD42b was conducted to exclude
CD31
+ microparticles of platelet origin. Platelet-derived micro-
particles were assessed with anti-CD62P. Confirmation of the
cellular origin of CD105
+ microparticles was made by the
presence of positive markers (CD90 and CD73), and the absence
of negative markers (VE-cadherin (CD144) and KDR) for MSCs.
Citrated whole blood was collected and centrifuged at 1800 g
for 15 minutes to prepare platelet-poor plasma [26]. Plasma
samples of 250 ml were thawed and centrifuged for 10 min at
19,800 g and 10uC to collect the microparticles [27]. The
microparticle pellet was resuspened with 20 ml of phosphate
buffered saline (PBS). Microparticles (5 ml) were then incubated
with fluorescent monoclonal antibodies (5 ml each): phycoerythrin
(PE)-labeled anti-CD31 (555446; BD Biosciences, San Jose, CA),
fluorescein isothiocyanate (FITC)–labeled anti-CD42b (555472;
BD Biosciences), allophycocyanin (APC)-labeled anti-CD90
(559869; BD Biosciences), APC-labeled AV (550475; BD Biosci-
ences), PE-labeled anti-CD62P (P-selectin; 55524; BD Bioscienc-
es), PE-labeled anti-CD184 (CXCR4; 555974; BD Biosciences),
APC-labeled anti-CD90 (559869; BD Biosciences), PE-labeled
anti-CD144 (VE-cadherin; 560410; BD Biosciences), APC-labeled
anto-CD73 (560847; BD Biosciences), PE-labeled KDR
(FAB357P, R&D Systems, Minneapolis, MN), and FITC-labeled
anti-CD105 (Endoglin; MCA1557F; Serotec, Oxford, UK).
The samples were incubated in the dark for 15 min at room
temperature, after which 500 ml1 6binding buffer was added, and
the samples were analyzed on a FACS Calibur flow cytometer
using the CellQuest software (BD Biosciences). Microparticles
were analyzed using a protocol with both forward scatter (FSC)
and side scatter (SSC) in logarithmic mode. Standard beads
1.0 mm in diameter (Sigma; Molecular Probes, Eugene, OR, USA)
were used for estimation of the microparticle size. For each
sample, 10,000 events were acquired. Microparticle levels were
corrected for an isotype control antibody, and dot plots with
control antibody. Microparticles smaller than 1 mm were quanti-
fied in specific populations (CD105
+, CXCR4
+, CD105
+/
CXCR4
+, CD105
+/90
+, CD105
+/144
2, CD105
+/144
2/90
+,
CD105
+/KDR
2, CD105
+/73
+, CD105
+KDR
2/73
+, CD31
+/
CD42b
2 and CD62P
+). Based on the number of events (N) in
the upper right (marker-positive and AV-positive) quadrant of the
flow cytometric analysis (FL-2 vs. FL-4, corrected for isotype
control antibody binding and autofluorescence), the number of
microparticles per liter of plasma was calculated as: n/L=N6(20/
5)6(550/V)6(10
6/250), where 5 (mL) is the volume of micropar-
ticle suspension, 20 is the total volume of washed microparticle
suspension, 550 is the total volume in the tube before analysis, V is
the sample volume analyzed, 10
6 is the number of microliters per
liter, and 250 is the original volume of plasma (Figure 1) [29,30].
Laboratory personnel who conducted the blood assays were
unaware of the subject’s clinical or laboratory data.
Plasma Concentrations of SDF-1a
SDF-1a–CXCR4 axis was associated with MSC homing to the
infracted hemisphere [31]. Circulating CXCR4
+ stem cells were
chemoattracted from peripheral blood to the brain by SDF-1a,
which is highly expressed in injured brain areas.
The plasma levels of the SDF-1a were evaluated to determine if
they were associated with the level of circulating CD105
+/
CXCR4
+ microparticles. The concentrations of SDF-1a were
measured using a commercially available, human SDF-1a
Quantikine immunoassays ELISA kit (R&D Systems, Minneapo-
lis, MN) according to the manufacturer’s protocols.
In vitro assay for CD105
+ microparticles derived from
human MSCs
A. Preparation of ischemic brain extract. Ischemic brain
tissue extracts were obtained 3 days after 90 min transient middle
cerebral artery occlusion. The ipsilateral hemispheres were
homogenized together by adding Dulbecco’s modified Eagle’s
medium (DMEM) (150 mg/mL) on the ice. After centrifugation
for 10 min at 10,000 g at 4uC, the supernatants were collected and
stored at 270uC [32,33].
B. Cell culture and ischemic conditioning. The same
methods were used in a previous work [17] for human bone
marrow MSCs (hMSCs) cell culture. Briefly, hMSCs were cultured
in a 175 cm
2 flask (Falcon, Franklin Lakes, NJ) with low-glucose
DMEM (Gibco, New York, NY) containing 10% fetal bovine
serum (Gibco, New York, NY) and 1% penicillin-streptomycin
(Sigma, St Louis, MO) in a humidified incubator at 37uC under
5% CO2. Nonadherent cells were removed when medium was
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80% confluence, they were harvested and subcultured.
hMSCs were incubated with Knockout DMEM (serum free
media, Gibco, New York, NY), 10% or 20% ischemic brain
extracts (BE). After 24 h incubation, conditioned media were
cleared from cell fragments by centrifugation at 2,500 g for
10 min at 10uC. The supernatants were stored at 270uC until
future analysis.
Statistical Methods
All data are presented as the mean 6 SD or number
(percentage) unless otherwise stated. The Shapiro-Wilk test was
used to test for normal distribution of continuous variables.
Because the distribution of microparticle levels was not normal
(p,0.05), we included log values that showed a normal
distribution. Correlations between two continuous variables were
conducted using Pearson correlation coefficients. For each
microparticle variable, we divided the levels into increasing
quartiles. Comparisons between groups were analyzed by a
Student’s t-test or analysis of variance (ANOVA), and categorical
variables were compared using the Pearson Chi-square test or
Fisher’s exact test. Analysis of covariance (ANCOVA) was used to
compare age- and sex-adjusted mean values for microparticles
between stroke patients and healthy subjects. Post hoc compar-
Figure 1. Typical examples of flow cytometric analysis. The levels of circulating CD105
+/AV
2 (Dotted rectangle) and CXCR4
+/AV
2 (Dashed and
dotted rectangle) were greater in patients with (B) large infarct than in those with (A) small infarct. (C) Most CD105
+ microparticles were CD90
+
(Rectangle). See text for abbreviations.
doi:10.1371/journal.pone.0037036.g001
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among groups. A multivariable logistic regression model was used
to evaluate the independent association between the initial severity
of stroke and the levels of circulating CD105
+/AV
2 and CD105
+/
CXCR4
+/AV
2 microparticles. The potential confounding factors
considered for inclusion in the model were risk factor profiles, time
interval between the onset of stroke and sampling, and serum
levels of SDF-1a. These factors were entered into a stepwise
logistic regression model, and the factors that were not significant
(p.0.2) were sequentially deleted from the full model. The results
are given as odds ratio (OR), as estimates of relative risk with 95%
CI. Significance was established at the p,0.05 level. All statistical
analyses were conducted using the SPSS software (SPSS 13.0;
SPSS, Chicago, IL).
Results
Characteristics of Study Population
The baseline characteristics and results of flow cytometric
analysis are summarized in Table 1. The age was younger and
female gender was more prevalent in the healthy subjects than in
the stroke patients. However, the risk factor profiles and serum
levels of SDF-1a did not differ between stroke patients and healthy
subjects. In the gated particles, the level of CD105
+/AV
2
microparticles was significantly increased in stroke patients when
compared to healthy subjects (p=0.036) (Table 1).
Microparticle Assay in Acute Stroke
We next searched for factors associated with a robust increase in
CD105
+/AV
2 microparticles in acute stroke setting. Among
patients with acute ischemic cerebrovascular disease, the levels of
CD105
+/AV
2 microparticles were increased as the baseline stroke
severity increased (r=0.208, p=0.028 for initial DWI lesion
volume; r=0.263, p=0.005 for initial NIHSS score) (Figure 2).
The levels of CD105
+/CXCR4
+/AV
2 microparticles were also
higher in patients with severe disability (r=0.192, p=0.046 for
initial NIHSS score) (Figure 2). In addition, the levels of CD90+/
AV
2 and CD105+/90+/AV
2 microparticles were positively
correlated with initial DWI lesion volume (r=0.349, p=0.013;
r=0.415, p=0.003, respectively).
Bivariate correlation analysis of data from acute stroke patients
showed that the CD105
+ microparticle phenotypes were positively
correlated (data not shown). However, there was no correlation
between the level of CD31
+/CD42
2 (endothelial) microparticles and
CD105
+/AV
2 (r=20.031, p=0.764) or CD105
+/CXCR4
+/AV
2
(r=0.044, p=0.668) microparticles levels, suggesting that CD105
+
microparticles originated from bone marrow rather than endothelial
cells. Similarly, therewas no correlation between the levels of CD62P
+
(platelet) microparticles and CD105
+ microparticle phenotypes.
Moreover, most CD105
+ microparticles were CD144
2,K D R
2,
CD90
+, and CD144
2/CD90
+ and approximately half of CD105+
microparticleswereCD73
+andKDR
2/73
+(Figure1CandFigure3).
Multivariate Testing
Patients with ischemic cerebrovascular disease were stratified
into four groups according to interquartile cutoff points of the
distribution of CD105
+/AV
2 microparticle levels (Table 2). The
levels of CD105
+ microparticles increased as the baseline stroke
severity increased (p,0.05 for both initial DWI lesion volume and
initial NIHSS score). The level of SDF-1a and time between
symptom onset and sampling did not differ among groups. The
risk factor profile did not affect the levels of circulating
microparticles (Table S1). A similar pattern was observed for
CD105
+/CXCR4
+/AV
2 microparticles (data not shown).
Multivariate testing showed that the initial severity of stroke was
independently associated with the level of circulating CD105
+/AV
2
microparticles (OR, 1.103 for 1 point increase in the NIHSS score on
admission; 95% CI, 1.032–1.178) after adjusting for other variables,
including the risk factor profiles, time after the onset of stroke, and
serum levels of SDF-1a (Table 3). Other factors did not significantly
add value to the level of circulating CD105
+/AV
2 microparticles.
CXCR4
+microparticles and SDF-1a
The levels of CD105
+/CXCR4
+ microparticles did not differ
between the stroke patients and healthy subjects (Table 1).
Table 1. Study population characteristics.
Acute stroke (n=111) Healthy subjects (n=50) P
Mean age 6 SD, year 66.0611.3 60.168.5 0.001
Female gender, n (%) 46 (41.4) 31 (62.0) 0.016
Hypertension, n (%) 67 (60.4) 24 (48.0) 0.143
Diabetes mellitus, n (%) 34 (30.6) 11 (22.0) 0.259
Dyslipidemia, n (%) 14 (12.6) 6 (12.0) 0.913
Atrial fibrillation, n (%) 13 (11.7) 2 (4.0) 0.098
SDF-1a, pg/ml 1678.36483.5 1687.36477.9 0.913
Microparticles, mean 6 SD, per ml
*
CD105
+ 1.62160.286 1.57460.230 0.282
CD105
+/AV
2 1.23260.278 1.11860.214 0.036
CD105
+/AV
+ 1.33260.376 1.32860.330 0.762
CD105
+/CXCR4
+ 1.06360.444 1.16260.300 0.139
CD105
+/CXCR4
+/AV
2 0.63360.430 0.71460.273 0.177
CD105
+/CXCR4
+/AV
+ 0.79660.510 0.92260.413 0.174
*Values after common logarithmic transformation.
Analysis of covariance was used to compare age- and sex-adjusted mean values for microparticles between groups.
See text for abbreviations.
doi:10.1371/journal.pone.0037036.t001
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+/CXCR4
+ microparticles
among CXCR4
+ microparticles was higher in the acute stroke
patients than in healthy subjects (29.5617.9% vs. 21.0616.9%,
p=0.011).
In the acute stroke setting, there was a poor correlation between
the serum level of CD105
+/CXCR4
+/AV
2 microparticles and
SDF-1a (r=20.042, p=0.674). The level of SDF-1a increased
with time after stroke onset (r=0.248, p=0.011), whereas the
levels of CD105
+/CXCR4
+/AV
2 microparticles decreased with
time after stroke onset (r=20.204, p=0.036) (Figure 2).
Ischemic brain tissue extracts induce in vitro CD105
+
microparticles derived from hMSCs
In order to further confirm that CD105
+ microparticles of
hMSCs are increased by ischemic injury, in vitro assay was
conducted. Compared to hMSCs treated by Knockout DMEM,
those conditioned by ischemic BE released more CD105
+
microparticles (p,0.01, DMEM vs. 10% ischemic BE; p,0.001,
DMEM vs. 20% ischemic BE). Moreover, hMSCs with 20%
ischemic BE derived more CD105
+ microparticles than those with
10% ischemic BE (p,0.01) (Figure 4).
Discussion
The main finding of this study was that there was a significant
relationship between circulating CD105
+/AV
2 microparticles and
the extent of infarct. The increase in the level of circulating
CD105
+ microparticles after acute stroke may be caused by (a)
increased circulating stem cells as a self-repair response after stroke
or by (b) increased apoptosis of circulating stem cells in response to
toxic conditions. Atheroprotective endothelial progenitor cells
(EPCs) may undergo fragmentation into microparticles when
exposed to cardiovascular risk factors [34]. Moreover, increased
microparticle shedding from EPCs may reduce circulating EPCs
levels and impair vascular repair processes. In patients with
extensive myocardial infarction, apoptotic progenitor cells
(CD34
+/AV
+) were increased, suggesting that progenitor CD34
+
cells are mobilized from the bone marrow but destroyed by
apoptosis due to increased oxidative stress [25].
Recently, the understanding of the role of microparticles in
various diseases has increased. Indeed, there is increasing evidence
that microparticles are functional [22] and facilitate intercellular
communication [35]. Platelet-derived and endothelial-derived
microparticles as well as microparticles from ischemic muscle
Figure 2. Correlation of microparticles with baseline stroke severity ((A) initial DWI lesion volume and (B) NIHSS score) and (C) time
since stroke onset. * Microparticle values after common logarithmic transformation. See text for abbreviations.
doi:10.1371/journal.pone.0037036.g002
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+/AV
2 microparticle levels in 111 patients with
ischemic cerebrovascular disease.
CD105
+/AV
2, per ml
* Q1 (,11.8) Q2 (11.9–17.3) Q3 (17.5–25.1) Q4 (.25.1) P
No. of patients 28 36 21 26
Age 64.8610.2 67.469.8 65.4611.5 66.3613.9 .847
Female gender, n (%) 14 (50) 10 (35.7) 11 (40.7) 11 (39.3) .733
Risk factor profile, n (%)
Hypertension 18 (64.3) 19 (67.9) 13 (48.1) 17 (60.7) .471
Diabetes 8 (28.6) 12 (42.9) 7 (25.9) 7 (25.0) .436
Dyslipidemia 4 (14.3) 5 (17.9) 4 (14.8) 1 (3.6) .371
Atrial fibrillation 0 (0) 2 (7.1) 6 (22.2) 5 (17.9) .023
{
Baseline stroke severity
DWI lesion volume, ml 7.7615.8 9.5625.1 12.9624.0 33.81657.5 .020
NIHSS score 4.7165.11 4.2564.20 6.0067.29 9.6467.51 .006
Time since symptom onset, days 3.7362.21 3.1762.03 2.4762.20 3.3862.58 .239
SDF-1a, pg/ml 1754.96432.2 1704.86384.0 1574.86441.4 1677.76636.9 .594
Endothelial microparticles, per ml
*
CD31
+/CD42
2 2.3060.50 2.3260.42 2.3760.24 2.1560.34 .283
CD31
+/CD42
2/AV
2 0.6760.73 0.5760.12 0.4560.10 0.3160.60 .352
CD31
+/CD42
2/AV
+ 2.2460.60 2.3160.42 2.3660.25 2.1460.35 .176
Platelet microparticles, per ml
*
CD62P
+ 1.5360.468 1.4360.38 1.5860.42 1.3560.34 .167
CD62P
+/AV
2 0.3860.51 0.1760.49 0.2460.39 0.2860.32 .366
CD62P
+/AV
+ 1.4860.48 1.3860.41 1.5560.43 1.3060.36 .148
*Values after common logarithmic transformation of the number of microparticles (per ml).
{related to larger infarct size in patients with atrial fibrillation.
doi:10.1371/journal.pone.0037036.t002
Figure 3. Cellular origin of CD105
+ microparticles. To know the cellular origin of CD105
+ microparticles, double labeling with anti-CD90, anti-
CD73 (positive markers for MSCs), anti-CD144, or KDR (negative markers for MSCs), and triple labeling with anti-CD90 and anti-CD 144, or anti-CD73 and
KDR were performed in patients with ischemic cerebrovascular disease. (a) Proportion of CD105
+/144
2, CD105
+/90
+, and CD105
+/144
2/90
+ among
CD105
+ microparticles. (b) Proportion of CD105
+/KDR
2, CD105
+/73
+, and CD105
+/KDR
2/73
+ among CD105
+ microparticles. See text for abbreviations.
doi:10.1371/journal.pone.0037036.g003
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Interestingly, however, the results of the present study showed that
circulating CD105
+/AV
2 (not apoptotic) microparticles were
increased in patients with extensive stroke, but that CD105
+/AV
+
microparticles were not associated with the extent of infarct. There
have been growing evidences that AV+ and AV2 microparticles
are produced under different circumstances and have distinct
properties or functions [38,39]. Since CD105+/AV2 micropar-
ticles were associated with the extent of stroke, but not CD105+/
AV+, we simply assume that extensive stroke may trigger the
formation of more AV2 microparticles from MSCs. However, the
precise mechanism should be elucidated through future studies.
Although circulating EPCs has been reported in patients with
ischemic insults, no studies have investigated circulating CD105
+
or CXCR4
+ cells or microparticles in stroke patients to date. Our
finding of increased circulating CD105
+ microparticle levels in
patients following severe stroke may reflect the increased level of
circulating MSCs or MSC-origin microparticles. Elevated
CD105
+ microparticles may be derived from either bone marrow
or cerebral endothelial cells [27,28]. However, our results showed
that CD105
+ microparticles were also positive for CD90 or CD73
(positive markers for MSCs) and negative for CD144 or KDR
(negative markers for MSCs). In addition, there was no correlation
between endothelial/platelet microparticles and CD105
+ micro-
particle phenotypes. Moreover, in vitro assay showed that CD105
+
microparticles derived from hMSCs were increased by ischemic
BE with dose-dependent manner. Together with the fact that most
bone marrow MSCs are CD105
+, it is conceivable that CD105
+
microparticles originated from bone marrow MSCs rather than
endothelial cells. To the best of our knowledge, this is the first
report of clinical evidence that MSCs are mobilized into
peripheral blood in patients after stroke.
It is well known that the SDF-1a receptor, CXCR4, is expressed
in bone marrow stromal cells. These cells migrated into ischemic
areas where chemokine SDF-1a expression has increased,
expressed neuronal or glial markers, increased neurogenesis and
reduced scar thickness [40]. Our finding of a poor correlation
between SDF-1a and CD105
+/CXCR4
+ microparticles was
unexpected and may have been caused by several reasons. First,
a different peak time between SDF-1a and CD105
+/CXCR4
+/
AV
2 microparticles after stroke may prevent a putative relation-
ship between serum chemokine and its receptor on microparticles.
In the present study, the SDF-1a levels increased, but the
CD105
+/CXCR4
+/AV
2 microparticles decreased with time after
the onset of stroke. Second, our data showed that approximately
70% of CD105
+ microparticles did not express CXCR4. In
addition to the difference in peak time between SDF-1a levels and
CD105
+/CXCR4
+/AV
2 microparticles, there may be chemo-
kines for CD105
+ microparticles other than the SDF-1a/CXCR4
axis. Our in vitro study suggests the possible existence of
chemokines other than SDF-1a that mediated the circulating
levels of CD105
+/AV
2 microparticles. In vitro migration analysis
using TranswellH comparing the chemoattractive capacity be-
tween ischemic brain extract and SDF-1a showed that the
migration of MSCs was higher when ischemic brain extract was
used than SDF-1a, and was not blocked by the treatment of
AMD3100 (an SDF-1a antagonist) (Figure S1). These findings
suggest that chemokines other than SDF-1a also mediated the
migration of MSCs. However, further studies are needed to
identify chemokines other than SDF-1a in stroke patients.
It should be noted that our study has several limitations. First,
laboratory methods for the isolation and detection of micropar-
ticles have not been settled to date, specifically in terms of the
centrifugation method and definition of microparticles. Most
studies have defined microparticles based on their size (less than
1 mm) [25,26,34,41], although some have defined them as AV
+
Table 3. Multivariate testing: odds ratio (95% CI) for the highest quartile of CD105
+ microparticle levels.
CD105
+/AV
2 microparticles CD105
+/CXCR4
+/AV
2 microparticles
Crude Multivariate P Crude Multivariate P
Initial DWI lesion volume, ml 1.008 (0.990–1.027) 0.999 (0.983–1.015)
NIHSS score on admission 1.083 (0.981–1.196) 1.103 (1.032–1.178) .004 1.097 (0.996–1.208) 1.086 (1.018–1.159) 0.015
Atrial fibrillation 2.227 (0.527–9.420) 3.819 (0.961–15.17)
SDF-1a, pg/ml 1.000 (0.999–1.001) 1.000 (0.999–1.001)
Time since symptom onset, days 1.208 (0.963–1.517) 1.151 (0.914–1.448)
See text for abbreviations.
doi:10.1371/journal.pone.0037036.t003
Figure 4. In vitro assay for CD105
+ microparticles derived from
hMSCs. Compared to hMSCs treated by Knockout DMEM, those
conditioned by ischemic BE released more CD105
+ microparticles.
Values are median and interquartile range; n=6 per group. *p,0.01,
**p,0.001. See text for abbreviations.
doi:10.1371/journal.pone.0037036.g004
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(AV
+) progenitor cells were increased in response to acute ischemic
insult (acute coronary syndrome, especially in extensive coronary
artery disease), suggesting that AV
+ microparticles could be a
marker for apoptotic or ‘‘non-functional’’ microparticles [25].
However, Leroyer et al. recently showed that microparticles
generated locally after limb muscle ischemia (mostly from
endothelial cells) triggered vasculogenesis, and they suggest that
microparticles may interact with bone marrow cells through
phosphatidyl serine (AV-binding site)-dependent binding [24].
Further studies are needed to compare the role of AV
+ and AV
2
microparticles in recovery after stroke. Second, although our data
showed that circulating CD105
+ microparticles were higher in
patients with extensive lesions, microparticles could also be
generated by systemic inflammatory response or ischemic brain
injury. However, parameters indicative for infection (such as C-
reactive protein) did not differ in response to different CD105
+
microparticle levels, making a systemic cause of the observed
differences unlikely. Finally, peripheral circulating CD105
+ cells
were not measured in this study.
In conclusion, our data showed that stroke triggers the
mobilization of bone marrow-derived microparticles, and the
level of CD105
+/AV
2 microparticles increased after extensive
infarcts, but decreased with time. Further studies are needed to
evaluate the role of bone marrow-origin microparticles in recovery
after stroke.
Supporting Information
Figure S1 Migration assay using rat bone marrow
mesenchymal stem cells (MSCs). Migration of rat bone
marrow MSCs was test using SDF-1a (B and E) and rat ischemic
brain extracts (C and F) as chemokines. Compared to control group
Knockout DMEM (A and D), migration of MSCs was increased in
both SDF-1a and ischemic brain extracts group. The degree of
increase in migration was greater in ischemic brain extracts group
than in SDF-1a group. After treatment of SDF-1a antagonist
(20 mM of AMD 3100), the migration of MSCs was nearly
completely blocked in the SDF-1a group (E) but not in the
ischemic brain extracts group (F) (see also right panel). These
findings suggest that chemokines other than SDF-1a play a role in
the migration of MSCs. Values were mean 6 SEM; n=4 per
group; *p,0.01 vs. AMD3100 untreated control. Methods for
migration assay: Migration assays were performed in transwell
system (Corning Life Sciences, Acton, MA), the lower side of the
transwell filter with 8 mm pore was coated for 1 hour at 37uC with
50 mg/ml Fibronectin (Sigma, St. Louis, MO). Rat bone marrow
MSCs (5610
4 cells) were placed in the upper chamber, and 600 ml
of migration medium with chemotactic factors or brain extract
supernatant were placed in the bottom chamber. Migration
observed in Knockout DMEM alone served as negative control.
We evaluated the chemotactic activity of SDF-1a (150 ng/ml). To
block chemotactic activity by receptor CXCR4, 20 mMo f
AMD3100 (Sigma, St. Louis, MO) was used. After 4 hours,
assays were terminated by removal of the medium from the upper
wells and filters were washed with PBS. Cells remaining on the
upper face of the filters were removed with a cotton wool swab.
Filters were fixed with methanol by submersion and stained with
toluidine blue (Sigma, St. Louis, MO) solution for 5 minutes and
then air dried. Filters cut out with a scalpel were mounted onto
glass slides, putting the lower face on the top. Stained cells in 5
fields were counted manually under 6100 magnification using
light microscopy. Data were expressed as percentages of cells
related to that of the negative control.
(TIF)
Table S1 Microparticle levels (mean±SD, per ml
a) and
risk factor profiles.
(DOC)
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